Approved for use through 07/31/200. 5/08 89/51/200.

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient D. Patient Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient D. Patient Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient D. Patient Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient D. Patient Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient D. Patient Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient D. Patient D. Patient Office, U.S. DEPARTMENT OF COMMENTS

U.S. Patient D. Pat

STATEMENT UNDER 37 CFR 3.73(b)
Applicant/Patent Owner: Andrew David BACON et al.
Application No /Patent         10/520,169         Filed/Issue Date:         (Int1) July 7, 2003
Entitled: METHOD TO ENHANCE AN IMMUNE RESPONSE OF NUCLEIC ACID VACCINATION
LIPOXEN TECHNOLOGIES LIMITED , a Corporation (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is:
the assignee of the entire right, title, and interest; or
2 an assignee of less than the entire right, title and interest.
(The extent (by percentage) of its ownership interest is%) in the patent application/patent identified above by virtue of either:
A. X assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 016583
Frame 0491 , or a true copy of the original assignment is attached.
OR
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:
1. From: To:
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
From:To:To:To:To:
Reel , Frame , or for which a copy thereof is attached.
3 From: To:
The document was recorded in the United States Patent and Trademark Office at
Reel , Frame , or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet.
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assigne was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.1. [NOTE: A separate copy (i.e., a time copy of he original assignment downounce)(s) must be submitted to Assignment Oxion in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See NFRF 302.06)
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.
27/09/57 Signature 27/09/57
Gregory Gregory advs Telephone Number
Director & Chief Scientific Officer